Annual Report 2024

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2024 86 The United Laboratories International Holdings Limited Annual Report 2024 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (b) Other segment information Amounts included in the measurement of segment profit or loss: For the year ended 31 December 2024 Intermediate Bulk Finished products medicine products Unallocated Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Amortisation of intangible assets 1,925 – 17,561 – 19,486 Depreciation of right-of-use assets 2,872 8,920 3,232 1,154 16,178 Depreciation of property, plant and equipment 355,496 119,603 103,895 889 579,883 Net loss on disposal of property, plant and equipment 1,899 1,667 703 – 4,269 Written off of property, plant and equipment 8,618 7,712 6,967 – 23,297 Write-down of inventories (reversed) recognised (5,641) 793 (11,111) – (15,959) Impairment losses recognised 3,027 7,253 34,432 168 44,880